Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918237 · ClinicalTrials.gov registry record · NA
Pilot Study to Test the Effects of Arctiva on Mild to Moderate Eczema
A NA study of Atopic Dermatitis Eczema, sponsored by ClinOhio Research Services.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05918237: Completed NA study of Atopic Dermatitis Eczema, sponsored by ClinOhio Research Services.
NCT05918237 is a NA study of Atopic Dermatitis Eczema that has completed, run by ClinOhio Research Services. The registered enrollment target is 30 participants, below the 198-participant average among 8 other Atopic Dermatitis Eczema trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05918237, a NA study of Atopic Dermatitis Eczema, has completed, sponsored by ClinOhio Research Services.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Up to 30 participants with mild to moderate atopic dermatitis/eczema will be enrolled to apply study Investigational Product for 4 weeks.
Primary Outcome
Change from Baseline to Day 28 in overall Severity Scoring of Atopic Dermatitis Index (SCORAD)
Conditions Studied
Interventions
- OTHER Arctiva
Study Locations (1)
Ohio
- ClinOhio Research Services, LLC - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2023-04-28 |
| Phase | NA |
What the finished NCT05918237 record still lists
NCT05918237 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 198-participant average among 8 other Atopic Dermatitis Eczema trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Atopic Dermatitis Eczema appearing as the primary indexed condition, and to 1 intervention - of which Arctiva is the first listed.
NCT05918237 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05918237 about?
NCT05918237 is a clinical study titled "Pilot Study to Test the Effects of Arctiva on Mild to Moderate Eczema". Up to 30 participants with mild to moderate atopic dermatitis/eczema will be enrolled to apply study Investigational Product for 4 weeks.
What is the current status of trial NCT05918237?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2023-02-06. Estimated completion is 2023-04-28.
What conditions does trial NCT05918237 study?
This clinical trial studies the following conditions: Atopic Dermatitis Eczema.
What interventions are being tested in trial NCT05918237?
The interventions under investigation include: Arctiva (OTHER).
Who is sponsoring clinical trial NCT05918237?
This trial is sponsored by ClinOhio Research Services, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918237 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis Eczema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05918237's enrollment target sits among peer trials
30 7th of 8 higher than 2 of 8 other Atopic Dermatitis Eczema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis Eczema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
COMPLETED · NA
-
Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.
COMPLETED · NA
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
RECRUITING · Phase 2
-
Seal, Stopping Eczema and Allergy Study
ACTIVE NOT RECRUITING · Phase 2
-
Breast Milk: Influence of the Micro-transcriptome Profile on Atopy in Children Over Time
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI